Abstract:Background Bladder cancer (BC) is regarded as one of the most fatal cancer around the world. Nevertheless, there still lack of sufficient markers to predict the prognosis of BC patients. Herein, we aim to establish a prognosis predicting signature based on long-noncoding RNA (lncRNA) for the invasive BC patients. Methods The lncRNA expression profile was downloaded from The Cancer Genome Atlas (TCGA) database, along with the correlated clinicopathological information. The univariate Cox regression test was employed to screen out the recurrence-free survival (RFS)-related lncRNAs. Then, the LASSO method was conducted to construct the signature based on these RFS-related lncRNA candidates. Genes correlated with these fourteen lncRNAs were extracted from the mRNA expression profile, with the Pearson correlation coefficient > 0.60 or < − 0.40. Subsequently, the Proteomap pathway enrichment analyses were conducted to classify the function of these correlated genes. Furthermore, the multivariate analyses were executed to reveal the independent role of the proposed signature with the clinicopathological features. Results We established an lncRNA-based RFS predicting signature by the LASSO Cox regression test, and proved its usage and stability on both the training and validation cohorts by the Kaplan-Meier and receiver operating characteristic (ROC) curves. Notably, the multivariate Cox regression analysis found that our classifier was an independent indicator for muscle-invasive BC patients rather than sex, age and tumor grade, with higher predictive value than the existing ones. Besides, we did the pathway analyses for these genes that highly correlated with the proposed fourteen lncRNAs, as well as the differentially expressed genes (DEGs) derived from the high-risk vs. low-risk groups, and the recurrence vs. non-recurrence groups, respectively. Notably, these results were consistent, and these genes were mostly enriched in the transcription factors, G protein-coupled receptors, MAPK signaling pathways, which were proved significantly associated with tumor progression and drug resistance. Conclusions Our results suggested that the fourteen-lncRNA-based RFS predicting signature is an independent indicator for BC patients. Further prospective studies with more samples are needed to verify our findings.

RNA-seq profiling identified a three-lncRNA panel in serum as potential biomarker for muscle-invasive bladder cancer

Prognostic Implications of Necroptosis-Related Long Noncoding RNA Signatures in Muscle-Invasive Bladder Cancer

A Novel DNA Methylation Signature As an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer

Serum Microrna Expression Signatures As Novel Noninvasive Biomarkers for Prediction and Prognosis of Muscle-Invasive Bladder Cancer.

Identification of a Serum Circulating Lncrna Panel for the Diagnosis and Recurrence Prediction of Bladder Cancer

Identification of a Three-Mirna Panel in Serum for Bladder Cancer Diagnosis by a Diagnostic Test

Serum Microrna Expression Signatures Identified from Genome‐wide Microrna Profiling Serve As Novel Noninvasive Biomarkers for Diagnosis and Recurrence of Bladder Cancer

Serum Micrornas As Predictors of Risk for Non-Muscle Invasive Bladder Cancer.

Cell-free Microrna Expression Signatures in Urine Serve As Novel Noninvasive Biomarkers for Diagnosis and Recurrence Prediction of Bladder Cancer

Abstract 5062: Serum Microrna Profiling in Non-Muscle Invasive Bladder Cancer

Combination of Urine Exosomal mRNAs and lncRNAs as Novel Diagnostic Biomarkers for Bladder Cancer

Urinary exosomal long non-coding RNAs as noninvasive biomarkers for diagnosis of bladder cancer by RNA sequencing

The long noncoding RNA SUMO1P3 as urinary biomarker for monitoring bladder cancer progression

Evaluation of Serum Exosomal LncRNA-based Biomarker Panel for Diagnosis and Recurrence Prediction of Bladder Cancer

Expression Signatures of Exosomal Long Non-Coding RNAs in Urine Serve As Novel Non-Invasive Biomarkers for Diagnosis and Recurrence Prediction of Bladder Cancer

Panel containing four serum microRNAs has potential to diagnose bladder cancer

A novel messenger RNA and long noncoding RNA signature associated with the progression of nonmuscle invasive bladder cancer.

A Four-Mirna Signature in Serum As a Biomarker for Bladder Cancer Diagnosis.

Circulating lncRNAs as noninvasive biomarkers in bladder cancer: A diagnostic meta-analysis based on 15 published articles

A Novel Biomarker Based on Mirna to Predict the Prognosis of Muscle-Invasive Bladder Urothelial Carcinoma

A prognostic index based on a fourteen long non-coding RNA signature to predict the recurrence-free survival for muscle-invasive bladder cancer patients